The Estonian Health Board has issued a strong recommendation regarding the prescription of the flu medications Ebilfumin and Tamiflu due to their limited availability in the country. In light of this scarcity, healthcare providers, particularly family doctors, are advised to reserve these medications for patients who belong to high-risk groups, including the elderly, individuals with chronic health conditions, and pregnant women. This decision underscores the importance of prioritizing vulnerable populations during the flu season when the demand for antiviral medications typically rises.

The recommendation comes at a time when flu cases are on the rise in Estonia, creating a surge in demand for these essential medications. The Health Board's guidelines are part of a broader strategy to ensure that those most at risk of severe complications from the flu virus have access to necessary treatments while conserving resources for future use. By restricting prescriptions to high-risk patients, the Health Board aims to mitigate the impact of the flu on the healthcare system and maintain adequate supplies for those in genuine need.

This situation also raises questions about the overall preparedness of Estonia's healthcare system in managing seasonal outbreaks and the availability of antiviral medications. As flu seasons can vary in severity, the reliance on a limited number of antivirals may highlight the need for broader public health strategies, including vaccination campaigns and increased production of antiviral drugs to ensure all populations have access to effective treatments.